US-based diagnostic tests provider Chembio Diagnostics has partnered with Swiss-based Foundation for Innovative New Diagnostics (FIND) to develop a point-of-care (POC) test, DPP Fever Panel Assay, to detect several acute febrile illnesses in the Asia Pacific region.

The firms will be working over the coming year to develop a simple, rapid and cost-effective test using Chembio’s Dual Path Platform (DPP) technology.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new multiplex test will be designed to simultaneously identify multiple life-threatening acute febrile diseases, contrary to the existing POC tests.

Chembio chief executive officer John Sperzel said: "We are pleased to collaborate with FIND toward the development of an Asia Pacific fever panel, based on our patented DPP technology.

"We are pleased to collaborate with FIND toward the development of an Asia Pacific fever panel, based on our patented DPP technology."

"We believe our platform offers the ability to develop rapid diagnostic tests that are simple, cost-effective and capable of testing for multiple pathogens simultaneously.

"Developing such a test, to address the most common causes of fever in Asia Pacific, is aligned with our growth strategy and supports our recent decision to acquire Malaysia-based RVR Diagnostics.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The assay will include nine tests and a quality control targeting parasitic, viral and bacterial pathogens common in the Asia Pacific region.

It will focus on fever symptoms, causing pathogens such as malaria species, dengue virus, Zika virus, chikungunya virus, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei and Orientia tsutsugamushi.

Chembio and FIND have previously partnered to develop a fever panel for four diseases, including Ebola and Marburg, with outbreak potential in Africa and South America. The panel is currently undergoing field testing in these countries.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact